Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2024

Core Insights - Axogen, Inc. reported preliminary unaudited financial results for the fourth quarter and full year of 2024, indicating strong growth in revenue and operational efficiency [1][3][6] - The company anticipates hosting an Investor Day on March 4, 2025, to outline future strategic priorities [3] Financial Performance - Fourth quarter revenue is expected to be approximately $49.4 million, reflecting a 15.1$187.3 million, representing a 17.8% increase over the full year of 2023 [6] - The expected gross margin for the full year is above 75.5% [6] - Cash, cash equivalents, and investments are expected to total approximately $39.5 million as of December 31, 2024, an increase of about$2.5 million from the end of 2023 [6] Business Strategy and Product Portfolio - The company focuses on improving commercial strategies, particularly in high-potential accounts within Extremities and OMF-Head & Neck applications [6] - Axogen's product portfolio includes various innovative solutions for peripheral nerve repair, such as Avance® Nerve Graft and Axoguard Nerve Connector® [5][7] - The company aims to make peripheral nerve care the standard of care for all patients, emphasizing the importance of restoring nerve function and quality of life [4][3]